Allergy Therapeutics plc (AGYTF) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Allergy Therapeutics plc's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
-9.46
Burn Risk
P/B Ratio
-13.44
Equity Deficit
Earnings Yield
-10.59%
Yield Gap
Profitability Health
2025Return on Equity
142.35%
Strong
WeakModerateStrong
Operating Margin
-53.60%
Weak
WeakModerateStrong
Net Profit Margin
-72.91%
Weak
WeakModerateStrong
Growth Indicators
2025Revenue Growth
36.89%
Strong
WeakModerateStrong
Net Income Growth
-36.99%
Weak
WeakModerateStrong
EPS Growth
21.50%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
1.28
Moderate
WeakModerateStrong
Quick Ratio
0.76
Weak
WeakModerateStrong
Asset Turnover
0.81x
Moderate
WeakModerateStrong
Inventory Turnover
2.15x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-8.44%
Weak
WeakModerateStrong
EV / Free Cash Flow
-13.33x
Strong
WeakModerateStrong
Net Debt / EBITDA
-1.61x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
1.371
Strong
WeakModerateStrong
Return on Invested Capital
-69.33%
Weak
WeakModerateStrong
Cash Conversion Cycle
167.85 days
Weak
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for AGYTF.
View Financial Statements